Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB
2 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for cognitive dysfunction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |